Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT03187509 : Weight-Based Torsemide Dosing in Subjects With Heart Failure
PhasePhase 4
AgesMin: 18 Years Max: 90 Years
Inclusion Criteria:

1. All subjects with admission diagnosis of heart failure, including heart failure with
reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF) treated with
loop diuretics during hospitalization

2. Must be at least 18 years old at time of enrollment

3. Must have reliable access to a telephone, and be able to speak and understand English
or Spanish over a telephone connection

Exclusion Criteria:

1. Any subject who is currently pregnant

2. Any subject with end-stage renal disease requiring hemodialysis

3. Any subject with serum potassium concentration < 3.5 mEq/L at discharge

4. Any subject with serum magnesium concentration < 1.4 mg/dL at discharge

5. Any subject with a known history of allergic reaction to loop diuretics

6. Any subject with known severe stenotic valvular heart disease

7. Any subject who requires chronic inotropic pharmacotherapy

8. Any subject undergoing evaluation for cardiac transplantation or left-ventricular
assist device

9. Any subject who is not able to provide informed consent
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557